Please select the eligibility criteria that correspond to the clinical trial below.
Title: Multicenter, Open-label, Randomized, 24 Months Follow-up, Two Arm Study to Compare the Efficacy of Everolimus in Improving the Cardiovascular Profile in a Regimen With Mycophenolic Acid vs. a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients.
Brief Summary: The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant patients


Options:
A: Inclusion Criteria:

* low risk adult candidates for first renal transplants from living or deceased donors

Exclusion Criteria:

* receiving immunosuppressive therapy before transplantation;
* have received an investigational medication within the past 30 days;
* have a known contraindication to the administration of antithymocyte globulin;
* tested positive for human immunodeficiency virus (HIV);
* had had cancer (except nonmelanoma skin cancer) within the previous 2 years;
* Pregnant women, nursing mothers, and women of childbearing potential who will be not using condoms or oral contraceptives will be excluded;
* Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or class II.
B: Inclusion Criteria:

* Male and female patients of any race between 18 to 70 years old (inclusive)
* Patients who gave written informed consent to participate in the study

Exclusion Criteria:

* Recipients of multi-organ transplantation
* Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA) identical living donor kidney transplantation.
* Graft cold ischemia time greater than 40 hours.

Other protocol-defined inclusion/exclusion criteria may apply.
C: Inclusion Criteria:

* Received kidney transplant \> 6 months and \< 3 years prior to study enrollment
* Receiving immunosuppressive regimen that includes tacrolimus and mycophenolic acid
* Between 18 and 70 years of age
* Willing to provide written informed consent

Exclusion Criteria:

* Patients with an actual serum creatinine ≥ 2 mg/dl and/or eGFR≤ 40 ml/min and/or proteinuria≥ 500mg/day
* Patients who suffered from severe humoral and/or cellular rejection (≥ BANFF IIb, recurrent acute rejection or steroid resistant acute rejection in the previous years
* Patients who have severe hypercholesterolemia (\>350 mg/dL; \>9 mmol/L) or hypertriglyceridemia (\>500 mg/dL; \>8.5 mmol/L). Patients with controlled hyperlipidemia are acceptable.
* Diabetic patients
* Woman of child-bearing potential who is planning to become pregnant or is pregnant and/or lactating who is unwilling to use effective means of contraception
* Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements
* Any other medical condition that, in the opinion of the site investigator based on recall or chart review would interfere with completing the study
* Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment
D: Inclusion Criteria:

* Dialysis patients who will be receiving their first kidney transplant
* Weight over 88 pounds (lbs.)

Exclusion Criteria:

* Very high cholesterol levels
* Obesity
* Organ donor over 65 years of age if living; over 60 years of age if cadaveric.

Answer: C